Piper Jaffray analyst Matt O'Brien raised his price target on AtriCure to $30 and kept his Overweight rating after the company's analyst meeting, saying he has a better understating of its products. O'Brien notes that AtriCure is making progress with its CONVERGE trial, and if approved, it will be able to market its indication to clinicians in 2020. The analyst expects the new product flow to allow the company to meet or beat guidance in FY18 as well, while also citing its "reasonable valuation" of about 4-times the FY19 consensus revenue as a reason to start new positions.